Notable healthcare headlines for the week: Eli Lilly, Hims & Hers Health, and Merck in focus
Seeking Alpha News (Sun, 16-Aug 9:05 AM ET)
Baxter International Lifts Outlook Amid Margin Strains
TipRanks (Fri, 14-Aug 8:27 PM ET)
Baxter Announces Cash Tender Offers
Business Wire (Tue, 4-Aug 8:30 AM ET)
Baxter Lifts 2026 Outlook as Segment Growth and Tariff Refund Drive Q2 Results Above Expectations
Market Chameleon (Thu, 30-Jul 3:35 AM ET)
Baxter Reports Second-Quarter 2026 Results
Business Wire (Thu, 30-Jul 7:15 AM ET)
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
Business Wire (Thu, 9-Jul 4:10 PM ET)
Business Wire (Mon, 22-Jun 9:00 AM ET)
PRNewswire (Thu, 18-Jun 10:02 AM ET)
Baxter's Q1 2026 Results Show International Gains, Pharmaceutical Strength, and Steady Guidance
Market Chameleon (Thu, 30-Apr 3:36 AM ET)
Baxter's Q4 Results Highlight Shift to Innovation and International Growth Amid Ongoing Challenges
Market Chameleon (Thu, 12-Feb 2:32 AM ET)
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Baxter International trades on the NYSE stock market under the symbol BAX.
As of August 17, 2026, BAX stock price declined to $26.22 with 1,143,124 million shares trading.
BAX has a beta of 1.37, meaning it tends to be more sensitive to market movements. BAX has a correlation of 0.13 to the broad based SPY ETF.
BAX has a market cap of $13.56 billion. This is considered a Large Cap stock.
Last quarter Baxter International reported $3 billion in Revenue and $.54 earnings per share. This beat revenue expectation by $164 million and exceeded earnings estimates by $.17.
In the last 3 years, BAX traded as high as $44.01 and as low as $15.73.
The top ETF exchange traded funds that BAX belongs to (by Net Assets): VTI, VOO, VB, RSP, IVV.
BAX has underperformed the market in the last year with a price return of +8.1% while the SPY ETF gained +21.4%. However, in the short term, BAX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +47.5% vs +3.9% return in SPY. But in the last 2 weeks, BAX shares have been beat by the market, returning +0.2% compared to an SPY return of +3.8%.
BAX support price is $26.02 and resistance is $27.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BAX shares will trade within this expected range on the day.